NCT01367275终止2 期
Phase II Study of Second-line Irinotecan Plus Brivanib, a Dual Tyrosine Inhibitor of VEGFR and FGFR, in Metastatic Colorectal Cancer Patients Enriched for Elevated Levels of Plasma FGF Following Progression on Bevacizumab-based Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Number of Participants With Median Progression-Free Survival (PFS)
研究概览
简要总结
The goal of this clinical research study is to learn if adding brivanib to irinotecan can help control the disease in patients with colorectal cancer that has spread. The safety of this drug combination will also be studied.
详细描述
Study Drugs:
Brivanib is designed to keep cancer cells from receiving the blood supply they need. This may slow down the growth of cancer cells.
Irinotecan is designed to interfere with the DNA (genetic material) of cancer cells. This may slow down the growth and spread of cancer cells.
Study Drug Administration:
If you are found to be eligible to take part in this study, you will take brivanib by mouth 1 time every day. The study drug should be taken at the same time each day with a glass (about 8 ounces) of water. You can take it with or without food.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written Informed Consent.
- •Patient must have progressed on front-line chemotherapy treatment containing bevacizumab for histologically confirmed colorectal adenocarcinoma that is unresectable or metastatic. Progression is defined as either radiographic or clinical progression.
- •Patient must have measurable lesions as defined by RECIST version 1.1 criteria.
- •ECOG performance status 0-
- •Known bFGF level performed by a CLIA-certified laboratory performed during or within 12 weeks of last bevacizumab treatment
- •Enrollment in the "Assessment of Targeted Therapies Against Colorectal Cancer" (ATTACC) protocol 2009-
- •LVEF > 50% measured by 2-D echocardiogram
- •Bone marrow function defined as the following: An absolute neutrophil count (ANC) =/>1,500/mcl; Platelets =/>100,000/mcl; Hemoglobin =/> 8.5 g/dl.
- •Renal function defined as the following: Serum creatinine less than or equal to 1.5 x institutional upper limit normal (ULN).
- •Hepatic function defined as the following: Serum total bilirubin < 1.5 x ULN; AST (SGOT), ALT (SGPT) and alkaline phosphatase =/< 2.5 x ULN; Serum albumin =/> 2.5 g/dl; If liver involvement, AST, ALT, and alkaline phosphatase =/< 5.0 x ULN.
- •International normalized ratio (INR) =/< 2.3 or Prothrombin Time (PT) =/< 6 seconds above control unless patient is currently receiving warfarin therapy for the treatment or prevention of venous thrombosis.
- •Men and women, age =/> 18 years.
- •A male subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study [and for up to 12 weeks after the last dose of study drug] to minimize the risk of pregnancy. If the partner is pregnant or breastfeeding, the subject must use a condom.
- •Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancy. WOCBP must have a negative serum or urine pregnancy test within 72 hours before the start of the investigational product.
排除标准
- •Women who are pregnant or breastfeeding.
- •Patients with brain metastases.
- •Patients with resectable colorectal cancer or non-adenocarcinoma cancer of the colon or rectum.
- •Patients who have had prior therapy with brivanib, anti-PDGFR (platelet-derived growth factor receptor) or anti-FGFR (fibroblast growth factor receptor) therapy.
- •Recent (within 4 weeks of the first study drug administration), or planned participation in another experimental therapeutic drug study.
- •Recent (within 4 weeks of the first study drug administration) infusion of bevacizumab therapy.
- •Prior irinotecan chemotherapy.
- •Prior full field radiotherapy =/<4 weeks or limited field radiotherapy =/<2 weeks prior to first study drug administration.
- •Recent use (within 4 weeks of first study drug administration) of St. John's Wort.
- •Patients with a history of thrombotic or embolic events within the last six months such as a cerebrovascular accident (including transient ischemic attacks), pulmonary embolism.
- •Patients with gastrointestinal bleeding or any other hemorrhage/bleeding event CTCAE (version 4.0) Grade 4 within 30 days prior to first study drug administration
- •Patients with uncontrolled or significant cardiovascular disease including: i) Active coronary artery disease, unstable or newly diagnosed angina or myocardial infarction < 12 months prior to first study drug administration. ii) Class III-IV New York Heart Association (NYHA) congestive heart failure. iii) Uncontrolled hypertension (Systolic blood pressure [BP] > 150 mmHg and diastolic BP > 90 mmHg for 24 hours) despite optimal medical management. Blood pressure must be below 140/90 mmHg at screening. Subjects with a history of hypertension who are receiving treatment with calcium channel blockers that are CYP3A4 substrates should be changed to an alternative antihypertensive medication prior to first study drug administration. iv) Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin. v) QTc (Fridericia) prolongation >450 msec. vi) Subjects with valvular heart disease =/> CTCAE (Ver. 4.0) Gr
- •vii) Left ventricular ejection fraction (LVEF) < 50%.
- •Active infection, less than 7 days after completing systemic antibiotic therapy.
- •History of non-healing wounds or ulcers, or bone fractures within 3 months prior to first study drug administration.
- •Major surgical procedure, open biopsy, or significant traumatic injury less than 3 weeks or those who receive minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 1 week from first dose of first study drug administration.
- •Inability to swallow tablets or untreated malabsorption syndrome.
- •Pre-existing thyroid abnormality with thyroid function that can not be maintained in the normal range with medication.
- •History of human immunodeficiency virus (HIV).
- •Patients with centrally cavitating lung lesions.
- •Known bleeding diathesis.
- •Inability to comply with study and/or follow-up procedures.
- •Patients with known glomerular nephritis.
- •Patients with known polycythemia.
- •Patients with known Gilbert's syndrome.
- •Women with a positive pregnancy test.
- •Patients with hyponatremia (sodium < 130 mmol/L).
- •Baseline serum potassium < 3.5 mmol/L (potassium supplementation may be given to restore the serum potassium above this level prior to study entry).
- •Baseline serum calcium < 8.4 mg/dL (calcium supplementation may be given to restore the serum calcium above this level prior to study entry).
- •Baseline serum magnesium < 1.5 mg/dL (magnesium supplementation may be given to restore the serum magnesium above this level prior to study entry).
- •Known or suspected history of allergy to brivanib or any agents given in association with this study.
- •Prisoners or subjects who are involuntarily incarcerated. Patients who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.
研究组 & 干预措施
Brivanib + Irinotecan
Experimental
Brivanib 800 mg orally daily Days 1-14, and Irinotecan intravenously 180 mg/m^2 on Day 1.
干预措施: Brivanib (Drug)
Brivanib + Irinotecan
Experimental
Brivanib 800 mg orally daily Days 1-14, and Irinotecan intravenously 180 mg/m^2 on Day 1.
干预措施: Irinotecan (Drug)
结局指标
主要结局
Number of Participants With Median Progression-Free Survival (PFS)
时间窗: Enrollment (baseline) to disease progression or death, followed each 14 day treatment then every 2 months,up to 100 week
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Irinotecan and Bevacizumab for Recurrent Ovarian CancerFallopian Tube CancerOvarian CancerPrimary Peritoneal CarcinomaNCT01091259NYU Langone Health29
终止
2 期
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal CancerColorectal CancerNCT01060423Hans-Joachim Schmoll, MD8
已完成
2 期
A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid TumorsNeoplasmsNCT00057473Bristol-Myers Squibb
已完成
2 期
Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung CancerCarcinoma, Small Cell LungLung CancerNCT00308529SCRI Development Innovations, LLC55
撤回
2 期
Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)Lung Cancer, Nonsmall Cell, Stage INCT02950038M.D. Anderson Cancer Center